Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ARV-471 on Rosuvastatin PK in Healthy Participants
NCT05652660Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration of Rosuvastatin and Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration of Rosuvastatin. Started Dec 2022; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05652660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652660.